WallStreetZenWallStreetZen

How to Buy Amedisys Stock

Amedisys Inc

Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care.

Amedisys stock last closed at $71.00, up 1.73% from the previous day, and has decreased 57.6% in one year. It has underperformed other stocks in the Medical Care Facilities industry by 0.39 percentage points. Amedisys stock is currently +2.36% from its 52-week low of $69.37, and -60.54% from its 52-week high of $179.91.

As of Mar 24, 2023, there are 32.55M shares of AMED outstanding. The market cap of AMED is $2.31B. In the last 24 hours, 251,869 AMED shares were traded.

How to Buy Amedisys Stock

Not sure how to invest in Amedisys stock? Here's how.
  1. Decide where to buy Amedisys stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Amedisys stock.
  2. Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
  3. Deposit funds into your investment account: Choose your method of payment and add your information.
  4. Analyze Amedisys stock: The Amedisys ticker symbol is AMED. Is Amedisys stock a good investment? Should you buy shares of AMED? How do AMED's underlying business fundamentals look? Do top analysts think Amedisys is a good buy? Why has AMED's stock price moved recently? (Hint: Our stock research tools can help you figure out if AMED is a good stock to buy).
  5. Make your AMED purchase: Decide if you will purchase AMED shares at the current market price or use a limit order to purchase AMED stock at a specific price.
  6. Get the latest scoop on your AMED investment: Create a watchlist to monitor your position in Amedisys shares.

Step 1: Decide where to buy Amedisys stock

You will need an online brokerage account to access the NASDAQ market and buy AMED stock.

A brokerage account enables you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.

Our preferred brokerage: eToro

Based on our analysis, eToro is the best place to buy stocks. eToro gives you:

  • Invest in stocks with 0% commissions: Invest without commissions.
  • Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
  • Access to global financial markets: From Technology to Energy, New York to Hong Kong — you can fill your portfolio with stocks from the globe's top exchanges.
  • Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
  • Security: eToro is a regulated and licensed brokerage platform.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your purchase of stock by opening an account with eToro today.

Open eToro Account

Step 2: Open a brokerage account

Now that you've picked your brokerage, it's time to fill out some personal information so you can invest in AMED stock today.

How to Start a New Account on eToro

  1. Click here to get started.
  2. Enter your personal info to create your new trading account.
  1. Submit your information by hitting the "Create Account" button.
Get started with eToro today

Step 3: Deposit funds into your investment account

Now that you have finished signing up on the best stock trading app, you can securely and quickly fund your account:

Check out the video below to see the process of depositing money into your new brokerage account.

Get started with eToro today

Step 4: Analyze Amedisys stock

After you have selected the best place to buy Amedisys stock, it's absolutely critical to analyze their stock before you buy, so you can understand the risk as well as the opportunity.

Amedisys Numbers

AMED Price
$71.00
1w %
-2.26%
1y %
-57.6%
5y %
15.33%
P/E
19.45x
P/B
2.2x
P/S
1.04x
PEG
0.83x
Revenue
$2.22B
Earnings
$118.61M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$2.31B
Next Earnings
Apr 25, 2023
Next Dividend
N/A

AMED Due Diligence Checks

WallStreetZen was created to help part-time investors perform better fundamental analysis in minutes instead of hours.

You can view all of the due diligence checks on AMED's stock page.

Is AMED stock overvalued?

Analysts use a variety of different financial metrics, analyses, models, and charts to gauge AMED's true value.

Using relative valuations methods:

  • AMED could be overvalued based on its P/E ratio of 19.45x, relative to Medical Care Facilities industry P/E ratio of 7.32x
  • AMED could be undervalued based on its P/B ratio of 2.2x, relative to Medical Care Facilities industry P/B ratio of 4.57x
  • AMED could be undervalued based on its PEG ratio of 0.83x

You can access additional valuation research on AMED's stock here.

AMED Financial Health Summary

Passed Financial Due Diligence Checks:

  • AMED's operating cash flow of $133.28M allows it to safely service it's debt of $537.94M.
  • There are more short-term assets than short-term liabilities on the AMED balance sheet.
  • AMED earnings of $183.38M is not sufficient to cover its interest payments.

Failed Financial Due Diligence Checks:

  • Total AMED debt is higher than 5 years ago, relative to shareholder equity.
  • AMED has a relatively high debt to equity ratio of 0.83.
  • AMED profit margin has gone down from 9.4% to 5.3% in the past year.
  • There are more long-term liabilities than short-term assets on the AMED balance sheet.

Is Amedisys stock a Buy, Hold, or Sell, according to Wall Street analysts?

Out of 14 Wall Street analysts who give ratings on AMED, the consensus analyst rating on Amedisys is a Buy

It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.

Latest AMED Analyst Recommendations

Bill Sutherland, a top 11% analyst from Benchmark reiterates AMED with a strong buy rating and maintains their AMED price target from $115.00 to $115.00, on Mar 14, 2023.

Scott Fidel, a top 10% analyst from Stephens & Co. reiterates AMED with a hold rating and maintains their AMED price target from $103.00 to $103.00, on Mar 14, 2023.

Steven Valiquette, a bottom 10% analyst from Barclays initiates coverage on AMED with a hold rating and announces their AMED price target of $93.00, on Mar 13, 2023.

Jonathan Yong, a bottom 9% analyst from Credit Suisse reiterates AMED with a buy rating and maintains their AMED price target from $115.00 to $115.00, on Feb 27, 2023.

Ben Hendrix, a bottom 20% analyst from RBC Capital maintains AMED with a buy rating and lowers their AMED price target from $114.00 to $111.00, on Feb 21, 2023.

You can dig deeper into what analysts are forecasting on the Amedisys stock forecast page.

AMED Technical Indicators

SMA10
74.02
SMA20
80.12
SMA50
88.14
SMA100
87.15
SMA200
100.41
MACD
-5.02
MACD Signal
-4.4
MACD Histogram
-0.62
RSI
35.38
Stochastic %K
12.95
Stochastic %D
6.8
StochRSI %K
37.83
StochRSI %D
21.04

AMED Revenue

Last year, AMED earnings were $118.61M. Over the past five year, AMED's earnings have grown by 32.32% per year. This was faster than the Medical Care Facilities industry average of 16.38%.

Last year, AMED revenue was $2.22B. Over the past 5 year, AMED's revenue has increased by 8.03% per year. This was slower than the Medical Care Facilities industry average of 15.66%.

Dive into AMED's earnings and revenue performance here.

Who is buying/selling AMED?

In the past year, executives and large shareholders at AMED have sold more shares than they have bought.

Michael Paul North, Chief Information Officer of AMED, was the latest AMED insider to sell. They sold $510,628.44 worth of AMED stock on Mar 3, 2023.

Dig into more about who owns AMED shares here.

Can I get consistent income from AMED stock?

No, Amedisys doesn't provide an income stream by paying out dividends.

Get analysis from other traders

One of the major reasons eToro is our favorite brokerage is because of its social trading community.

Click below to find out what other investors have to say.

Step 5: Make your AMED purchase

There are two main types of orders:

  • Market order: A market order is an order to buy or sell a stock at the best price on the market.
    Market orders are mostly the easiest way to buy.
  • Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
    If you want to be sure you're buying or selling at a given price, use a limit order.

Press the Open button and your broker will execute the order.

If you want additional help buying stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Get the latest scoop on your AMED investment

Now that you own some AMED stock, you'll want to stay up-to-date on your new investment.

Make a watchlist to track your AMED stock.

AMED Feed

How to Buy Stock in Amedisys

To summarize, here are the 6 steps to buy Amedisys stock:

  1. Decide where to buy Amedisys stock
  2. Open a brokerage account
  3. Deposit funds into your investment account
  4. Analyze Amedisys stock
  5. Make your AMED purchase
  6. Get the latest scoop on your AMED investment

If you require a brokerage, eToro is our favorite option.

Get Started with eToro Today

If you would like to get the latest news on your investment in Amedisys, get started below.

NASDAQ: AMED
$71.00+1.21 (+1.73%)
Updated Mar 24, 2023
Open eToro Account
NASDAQ: AMED
$71.00+1.21 (+1.73%)
Updated Mar 24, 2023
Open eToro Account

FAQ

How much does it cost to buy one Amedisys share?

As of Mar 24, 2023, it costs $71.00 to buy one share of Amedisys stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.141 shares of AMED.

Get Started with eToro Today

Is now a good time to buy Amedisys stock?

According to 14 Wall Street analysts who monitor Amedisys, their consensus recommendation is to buy Amedisys stock.

What is the best way to buy Amedisys stock?

One way to place an order for Amedisys stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.